Aadi Bioscience, Inc. financial data

Symbol
AADI on Nasdaq
Industry
Pharmaceutical Preparations
Location
17383 Sunset Avenue, Suite A250, Pacific Palisades, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Aerpio Pharmaceuticals, Inc. (to 8/23/2021), ZETA ACQUISITION CORP II (to 3/13/2017)
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 509 % -49.4%
Quick Ratio 24.8 % +70%
Debt-to-equity 23.5 % +48.9%
Return On Equity -66.7 % -63.7%
Return On Assets -54 % -53.5%
Operating Margin -297 % +4.44%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24.6M shares +0.39%
Common Stock, Shares, Outstanding 24.6M shares +0.39%
Entity Public Float 111M USD -37.7%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 27M shares +0.49%
Weighted Average Number of Shares Outstanding, Diluted 27M shares +0.49%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 23.8M USD +10.6%
Research and Development Expense 51.3M USD +21.1%
Costs and Expenses 94.5M USD +6.85%
Operating Income (Loss) -70.7M USD -5.66%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.3M USD -12.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -65.4M USD -6.27%
Earnings Per Share, Basic -2.42 USD/shares -0.83%
Earnings Per Share, Diluted -2.42 USD/shares -0.83%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 41.1M USD -39.6%
Cash, Cash Equivalents, and Short-term Investments 78.6M USD -41.7%
Accounts Receivable, after Allowance for Credit Loss, Current 5.92M USD +61%
Inventory, Net 6.1M USD +76.4%
Assets, Current 93M USD -35.8%
Property, Plant and Equipment, Net 6M USD +99.8%
Operating Lease, Right-of-Use Asset 982K USD -27.2%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Other Assets, Noncurrent 1.63M USD -16.5%
Assets 102M USD -32.8%
Accounts Payable, Current 2.27M USD -21.8%
Accrued Liabilities, Current 7.34K USD
Liabilities, Current 22.1M USD +70.4%
Operating Lease, Liability, Noncurrent 682K USD -35.4%
Other Liabilities, Noncurrent 109K USD
Liabilities 22.8M USD +15.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -27K USD +38.6%
Retained Earnings (Accumulated Deficit) -302M USD -27.7%
Stockholders' Equity Attributable to Parent 78.8M USD -40%
Liabilities and Equity 102M USD -32.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.7M USD +7.78%
Net Cash Provided by (Used in) Financing Activities -10K USD -225%
Net Cash Provided by (Used in) Investing Activities 10.6M USD -35.4%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 24.6M shares +0.39%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.11M USD -83.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 58K USD 0%
Deferred Tax Assets, Valuation Allowance 72.1M USD +36.7%
Deferred Tax Assets, Gross 72.7K USD
Operating Lease, Liability 1.06M USD -28.1%
Depreciation 50K USD +16.3%
Payments to Acquire Property, Plant, and Equipment 739K USD -46%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -65.4M USD -6.17%
Lessee, Operating Lease, Liability, to be Paid 1.2M USD -29.6%
Property, Plant and Equipment, Gross 6.37M USD +99.9%
Operating Lease, Liability, Current 374K USD -9.44%
Lessee, Operating Lease, Liability, to be Paid, Year Two 231K USD -27.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 320K USD -37.5%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 143K USD -39.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 280K USD +21.2%
Deferred Tax Assets, Operating Loss Carryforwards 43.7M USD +13.3%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 7K USD +250%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.6M USD +36%
Lessee, Operating Lease, Liability, to be Paid, Year Four 109K USD -61.1%
Operating Lease, Payments 126K USD +1.61%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 0 USD -100%
Depreciation, Depletion and Amortization 50K USD +31.6%
Deferred Tax Assets, Net of Valuation Allowance 560K USD -4.44%
Interest Expense 231K USD +0.44%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%